missing translation for 'onlineSavingsMsg'
Learn More
Learn More
ERCC3 Mouse anti-Human, Clone: OTI6H8, TrueMAB™, Origene
Mouse Monoclonal Antibody
Brand: Origene Technologies TA809371S
This item is not returnable.
View return policy
Description
ERCC3 Monoclonal antibody specifically detects ERCC3 in Human samples. It is validated for Immunohistochemistry (Paraffin), Western BlotSpecifications
| ERCC3 | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
| P19447 | |
| Mouse | |
| Affinity chromatography | |
| RUO | |
| 2071 | |
| -20° C, Avoid Freeze/Thaw Cycles | |
| Liquid |
| Immunohistochemistry (Paraffin), Western Blot | |
| OTI6H8 | |
| Unconjugated | |
| Ercc3 | |
| Basic transcription factor 2 89 kDa subunit; BTF2; BTF2 p89; BTF2-p89; DNA excision repair protein ERCC-3; DNA repair helicase; DNA repair protein complementing XP-B cells; ERCC excision repair 3, TFIIH core complex helicase subunit; Ercc3; Ercc-3; excision repair 3; excision repair cross-complementation group 3; excision repair cross-complementing rodent repair deficiency, complementation group 3; General transcription and DNA repair factor IIH helicase subunit XPB; GTF2H; RAD25; TFIIH; TFIIH 89 kDa subunit; TFIIH basal transcription factor complex 89 kDa subunit; TFIIH basal transcription factor complex helicase XPB subunit; TFIIH p89; TFIIH subunit XPB; TTD2; Xeroderma pigmentosum group B-complementing protein; xeroderma pigmentosum, complementation group B; XPB; XPBC | |
| Human recombinant protein fragment corresponding to amino acids 191-436 of human ERCC3 produced in E.coli. | |
| 30 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG1 |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction